webinar register page

FDA's Missed Opportunities to Tackle Endocrine Disrupting Chemicals in Food
The Food and Drug Administration (FDA) recently decided to allow continued use of nine phthalates in plastics, paper, and adhesives that contact food or drinks. The agency originally approved these uses decades ago, and in response to petitions from public health advocates, acknowledged that it has not assessed the safety of phthalates since 1985. FDA officials published a separate request for information on the use and safety of the phthalates that will still be allowed. Studies have linked phthalate exposure to a range of serious human health harms, particularly in children.

Many groups have petitioned FDA to reconsider allowable levels of BPA in food packaging as well, including most recently members of the Endocrine Society. Extremely low levels of BPA exposure have been linked to a number of human health harms, including overactive immune responses, increased risk of breast cancer and infertility.

Dr. Maricel Maffini will provide an overview of FDA's approach to endocrine disruption in the assessment of chemicals in food packaging, focusing particularly on these recent actions on phthalates and BPA. Dr. Maffini is an independent consultant with more than 25 years of experience researching carcinogenesis, reproductive biology, and endocrine disruption.

Sharyle Patton, founder and director of Commonweal's Biomonitoring Resource Center, will moderate the webinar. It will last for 45 minutes and will be recorded for our archives.

This webinar series is sponsored by the EDC Strategies Partnership, which is co-chaired by Sharyle Patton along with Jerry Heindel and Sarah Howard (Environmental Health Sciences' Healthy Environment and Endocrine Disruptor Strategies HEEDS), Genon Jensen (Health and Environment Alliance, HEAL), and Kristin Schafer (Commonweal's CHE, the Collaborative on Health and the Environment).

Jul 6, 2022 10:00 AM in Pacific Time (US and Canada)

* Required information